Jakub Żołnierek
Jakub Żołnierek has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Adam Fałkowski
Lux Med Onkologia, Warsaw, Poland
1 shared publicationAleksandra Żołnierek
Faculty of Medicine, Medical University of Warsaw, Poland
1 shared publicationAnna Waśko-Grabowska
CSK MON WIM
1 shared publicationBeata Obrocka
CSK MON WIM
1 shared publication- Cezary Szczylik
Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland
1 shared publication Ewa Kuszatal
CSK MON WIM
1 shared publication
Latest Publications
- Open Access
- 19 August 2023
- Published by Medical Education in OncoReview
- Vol. 13 (2(50)) , 48-57
The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10
The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 – with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOR inhibitor necessitates a choice between two-drug immunotherapy or an antiangiogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.
- 19 August 2023
- Published by Medical Education in OncoReview
- Vol. 13 (2(50)) , 48-57
Open AccessThe first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10
The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 – with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOR inhibitor necessitates a choice between two-drug immunotherapy or an antiangiogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.
- Open Access
- 30 June 2023
- Published by VM Media Group sp. z o.o in Oncology in Clinical Practice
- Vol. 20 (2) , 136-143
Spectacular clinical benefit achieved by multidisciplinary management of a kidney cancer patient
The present study is a case report of a patient with a diagnosis of renal cell carcinoma with poor prospects, in whom long-term tumor control at the level of deep cytoreduction was achieved through aggressive multidisciplinary management using surgery, stereotactic radiotherapy, and sequential systemic therapy with immunotherapy based on a checkpoint inhibitor with anti-PDL1 activity combined with anti-angiogenic treatment, and by a non-selective tyrosine kinase inhibitor. The present study is a case report of a patient with a diagnosis of renal cell carcinoma with poor prospects, in whom long-term tumor control at the level of deep cytoreduction was achieved through aggressive multidisciplinary management using surgery, stereotactic radiotherapy, and sequential systemic therapy with immunotherapy based on a checkpoint inhibitor with anti-PDL1 activity combined with anti-angiogenic treatment, and by a non-selective tyrosine kinase inhibitor.
- 30 June 2023
- Published by VM Media Group sp. z o.o in Oncology in Clinical Practice
- Vol. 20 (2) , 136-143
Open AccessSpectacular clinical benefit achieved by multidisciplinary management of a kidney cancer patient
The present study is a case report of a patient with a diagnosis of renal cell carcinoma with poor prospects, in whom long-term tumor control at the level of deep cytoreduction was achieved through aggressive multidisciplinary management using surgery, stereotactic radiotherapy, and sequential systemic therapy with immunotherapy based on a checkpoint inhibitor with anti-PDL1 activity combined with anti-angiogenic treatment, and by a non-selective tyrosine kinase inhibitor. The present study is a case report of a patient with a diagnosis of renal cell carcinoma with poor prospects, in whom long-term tumor control at the level of deep cytoreduction was achieved through aggressive multidisciplinary management using surgery, stereotactic radiotherapy, and sequential systemic therapy with immunotherapy based on a checkpoint inhibitor with anti-PDL1 activity combined with anti-angiogenic treatment, and by a non-selective tyrosine kinase inhibitor.
- 10 January 2020
- Published by VM Media Group sp. z o.o in Oncology in Clinical Practice
- Vol. 15 (6) , 303-306
Enzalutamide in systemic treatment of prostate cancer
Prostate cancer is one of the most common tumours in the human population and the most frequently diagnosed among genitourinary tumours. Despite relatively high efficacy of systemic treatment in prostate cancer, it is still one of the most important causes of premature cancer mortality in men. There are several causes of this phenomenon. One of the most important reasons for such are complications of disease spread and localisation of metastatic lesions. Others include complications related to implemented treatment, especially if chemotherapy is being administered. However, it is still the specific biological transformation and tumour evolution into state of resistance to castration (CRPC), which develops with time and under hormonal therapy, that is the major clinical challenge. Progress in the field of molecular biology enabled identification of the crucial role of signal transduction pathway dependent on the androgen receptor (AR) in CRPC. Enzalutamide is the first anti-androgen that interferes with the mechanism of progression related to AR gene amplification and/or AR over-expression. The results of the PREVAIL phase 3 trial in a population of men with metastatic CRPC not previously exposed to docetaxel were presented at ASCO GU 2014. These data prove a significant advantage of enzalutamide use over placebo in regard to all study end-points. Enzalutamide is a drug that prolongs progression-free survival and overall survival in different populations of men with CRPC. Prostate cancer is one of the most common tumours in the human population and the most frequently diagnosed among genitourinary tumours. Despite relatively high efficacy of systemic treatment in prostate cancer, it is still one of the most important causes of premature cancer mortality in men. There are several causes of this phenomenon. One of the most important reasons for such are complications of disease spread and localisation of metastatic lesions. Others include complications related to implemented treatment, especially if chemotherapy is being administered. However, it is still the specific biological transformation and tumour evolution into state of resistance to castration (CRPC), which develops with time and under hormonal therapy, that is the major clinical challenge. Progress in the field of molecular biology enabled identification of the crucial role of signal transduction pathway dependent on the androgen receptor (AR) in CRPC. Enzalutamide is the first anti-androgen that interferes with the mechanism of progression related to AR gene amplification and/or AR over-expression. The results of the PREVAIL phase 3 trial in a population of men with metastatic CRPC not previously exposed to docetaxel were presented at ASCO GU 2014. These data prove a significant advantage of enzalutamide use over placebo in regard to all study end-points. Enzalutamide is a drug that prolongs progression-free survival and overall survival in different populations of men with CRPC.
- 10 January 2020
- Published by VM Media Group sp. z o.o in Oncology in Clinical Practice
- Vol. 15 (6) , 303-306
Enzalutamide in systemic treatment of prostate cancer
Prostate cancer is one of the most common tumours in the human population and the most frequently diagnosed among genitourinary tumours. Despite relatively high efficacy of systemic treatment in prostate cancer, it is still one of the most important causes of premature cancer mortality in men. There are several causes of this phenomenon. One of the most important reasons for such are complications of disease spread and localisation of metastatic lesions. Others include complications related to implemented treatment, especially if chemotherapy is being administered. However, it is still the specific biological transformation and tumour evolution into state of resistance to castration (CRPC), which develops with time and under hormonal therapy, that is the major clinical challenge. Progress in the field of molecular biology enabled identification of the crucial role of signal transduction pathway dependent on the androgen receptor (AR) in CRPC. Enzalutamide is the first anti-androgen that interferes with the mechanism of progression related to AR gene amplification and/or AR over-expression. The results of the PREVAIL phase 3 trial in a population of men with metastatic CRPC not previously exposed to docetaxel were presented at ASCO GU 2014. These data prove a significant advantage of enzalutamide use over placebo in regard to all study end-points. Enzalutamide is a drug that prolongs progression-free survival and overall survival in different populations of men with CRPC. Prostate cancer is one of the most common tumours in the human population and the most frequently diagnosed among genitourinary tumours. Despite relatively high efficacy of systemic treatment in prostate cancer, it is still one of the most important causes of premature cancer mortality in men. There are several causes of this phenomenon. One of the most important reasons for such are complications of disease spread and localisation of metastatic lesions. Others include complications related to implemented treatment, especially if chemotherapy is being administered. However, it is still the specific biological transformation and tumour evolution into state of resistance to castration (CRPC), which develops with time and under hormonal therapy, that is the major clinical challenge. Progress in the field of molecular biology enabled identification of the crucial role of signal transduction pathway dependent on the androgen receptor (AR) in CRPC. Enzalutamide is the first anti-androgen that interferes with the mechanism of progression related to AR gene amplification and/or AR over-expression. The results of the PREVAIL phase 3 trial in a population of men with metastatic CRPC not previously exposed to docetaxel were presented at ASCO GU 2014. These data prove a significant advantage of enzalutamide use over placebo in regard to all study end-points. Enzalutamide is a drug that prolongs progression-free survival and overall survival in different populations of men with CRPC.
- 27 August 2009
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (3) , 371-378
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases
This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC). The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w. Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047). Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.
- 27 August 2009
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (3) , 371-378
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases
This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC). The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w. Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047). Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.